Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• High-grade serous ovarian cancer (HGSOC) presents significant challenges due to low survival rates, lack of early detection, and limited treatment options.
• Forskolin exhibits anticancer properties but has poor in vivo applicability.
• Colforsin daropate, a water-soluble forskolin derivative, shares its mechanism of action and is approved for acute heart failure.

Purpose of the Study:

• To evaluate the therapeutic potential of colforsin daropate against high-grade serous ovarian cancer (HGSOC).
• To investigate the efficacy and safety of colforsin daropate in preclinical HGSOC models.

Main Methods:

• Assessed colforsin daropate's effects on HGSOC cell cycle, apoptosis, and invasion in vitro.
• Evaluated cytotoxicity in normal ovarian and fallopian tube cells.
• Determined in vivo efficacy in subcutaneous and intraperitoneal xenograft models, including combination therapy with cisplatin.
• Investigated the role of c-MYC in mediating antitumor effects.

Main Results:

• Colforsin daropate induced cell cycle arrest and apoptosis in HGSOC cells with minimal toxicity to normal cells.
• It inhibited HGSOC cell invasion in vitro.
• In vivo, colforsin daropate reduced tumor growth, synergized with cisplatin, and improved survival.
• Antitumor effects were partly attributed to reduced c-MYC levels and activity.

Conclusions:

• Colforsin daropate demonstrates significant preclinical efficacy as an HGSOC treatment.
• It exhibits a favorable safety profile, sparing normal cells.
• Colforsin daropate holds promise as a novel therapeutic agent, potentially enhancing conventional ovarian cancer treatments.